Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Glabellar Lines: full-pipeline trial registry
A small indexed set (5 trials) with no open enrollment listed right now.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · none currently recruiting · #3,391 of 28,707 conditions by registered trial count
Glabellar Lines: 5 US clinical trials tracked, none currently recruiting.
Glabellar Lines is the subject of 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 3 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Medy-Tox, running 2 of these trials.
Enrollment posture brief
Registry condition glabellar-lines
OPEN 0 | RECR 0% | LATE 3 | EARLY 2 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Glabellar Lines has no open enrollment in this registry pull (5 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Glabellar Lines on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Glabellar Lines is recruiting below its size-band peers.
0 of 5 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Glabellar Lines research.
Medy-Tox accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical Glabellar Lines enrolment sits around 116 participants.
Median target enrolment is 116 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.
-
Glabellar Lines research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
5 total, page 1 of 1
A Study to Evaluate AI-09 In Participants With Glabellar Lines
Eirion Therapeutics
NCT07321834
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
Medy-Tox
NCT04157686
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
Medy-Tox
NCT03732833
Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)
Allergan
NCT02176356
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
AbbVie
NCT05496335
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Glabellar Lines records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Glabellar Lines trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Glabellar Lines page
5 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Glabellar Lines trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Medy-Tox sponsors the most Glabellar Lines trials on record, review their full trial history before evaluating a specific study. See Medy-Tox's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glabellar Lines condition card totals 5 registered trials; most-linked intervention Placebo; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.